SINO BIOPHARMACEUTICAL

Sino Biopharm is a leading Chinese pharmaceutical company continuing to invest in Oncology, Hepatology, Respiratory and Surgery, exploring innovative therapies to improve the lives of patients. The company has strong manufacturing capabilities and broad patient access across China. Sino Biopharm is committed to bring innovation to address unmet healthcare needs globally. The company was listed on the Hong Kong Stock Exchange in 2000, and was selected as a component of the MSCI Global Standard Index in China in 2013; In 2018, it was selected as a constituent stock of Hang Seng Index;The company has been listed in the "Top 50 Global Pharmaceutical Enterprises" published by the authoritative American magazine Pharmaceutical Manager for four consecutive years, and has been rated as the "Top 50 Best Companies in Asia Pacific" by Forbes (Asia) for three consecutive years... invoX is a wholly owned subsidiary of Sino Biopharm headquartered in London, UK. Through three strategic acquisitions..

Also known as: Sino Biopharm, Sino Biopharmaceutical Co., Ltd

Primary location: Beijing China